PYC Therapeutics (PYC) AGM 2026 summary

Opening remarks and agenda

• Quorum was confirmed; the agenda covered FY26 financial reports, auditor questions, resolutions, the CEO update, shareholder questions and meeting close.

• Resolutions were decided by poll, with results to be announced after the CEO presentation.

Board and executive committee updates

• CFO Thomas joined during the year; management and clinical teams expanded in Australia and the U.S. to support four programs.

• Two additional directors are being sought through Russell Reynolds, targeting U.S. Phase II/III and FDA experience alongside finance, ECM or M&A skills; appointments are expected in Q1 2027.

• Peter Coleman and Professor Ian Constable AO were re-elected, with 93.93% and 93.62% of votes for, respectively.

Corporate governance

• Governance policies and procedures were refreshed and three board committee charters published in preparation for S&P/ASX 300 requirements.

• Directors plan to move from three-year terms to annual re-election; non-executive directors set a minimum shareholding equal to one year of total remuneration, with 40% of remuneration in equity rights subject to a holding period.

• Proportional takeover provisions were renewed for three years from the AGM, receiving 99.97% support; shareholders ratified the 85,489,067-share placement at $1.50 per share, with 99.88% support.